@article{c2f5a46efd064f749d55b90bcd006359,
title = "Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment",
abstract = "Breast cancer stem cells (BCSCs), which are characterized by a capacity for unlimited self-renewal and for generation of the bulk cancer cell population, play a critical role in cancer relapse and metastasis. Hypoxia is a common feature of the cancer microenvironment that stimulates the specification and maintenance of BCSCs. In this study, we found that hypoxia increased expression of adenosine receptor 2B (A2BR) in human breast cancer cells through the transcriptional activity of hypoxia-inducible factor 1. The binding of adenosine to A2BR promoted BCSC enrichment by activating protein kinase C-δ, which phosphorylated and activated the transcription factor STAT3, leading to increased expression of interleukin 6 and NANOG, two key mediators of the BCSC phenotype. Genetic or pharmacological inhibition of A2BR expression or activity decreased hypoxia-or adenosine-induced BCSC enrichment in vitro, and dramatically impaired tumor initiation and lung metastasis after implantation of MDA-MB-231 human breast cancer cells into the mammary fat pad of immunodeficient mice. These data provide evidence that targeting A2BR might be an effective strategy to eradicate BCSCs.",
keywords = "ADORA2B, Caffeine, HIF-1, Oxygen, Tumor-initiating cells",
author = "Jie Lan and Haiquan Lu and Debangshu Samanta and Shaima Salman and You Lu and Semenza, {Gregg L.}",
note = "Funding Information: ACKNOWLEDGMENTS. We thank Karen Padgett of Novus Biologicals for providing IgG and antibodies against A2BR, HIF-1β, HIF-2α, p-PKCδ (S645), PKCδ, p-STAT3 (S727), p-STAT3 (Y705), p-JAK2 (Y1007), JAK2, and NANOG. G.L.S. is an American Cancer Society Research Professor and the C. Michael Armstrong Professor at the Johns Hopkins University School of Medicine. This work was supported by the Emerson Collective Cancer Research Fund, American Cancer Society, and the Cindy Rosencrans Fund for Triple-Negative Breast Cancer. Funding Information: We thank Karen Padgett of Novus Biologicals for providing IgG and antibodies against A2BR, HIF-1β, HIF-2α, p-PKCδ (S645), PKCδ, p-STAT3 (S727), p-STAT3 (Y705), p-JAK2 (Y1007), JAK2, and NANOG. G.L.S. is an American Cancer Society Research Professor and the C. Michael Armstrong Professor at the Johns Hopkins University School of Medicine. This work was supported by the Emerson Collective Cancer Research Fund, American Cancer Society, and the Cindy Rosencrans Fund for Triple-Negative Breast Cancer. Publisher Copyright: {\textcopyright} 2018 National Academy of Sciences. All Rights Reserved.",
year = "2018",
month = oct,
day = "9",
doi = "10.1073/pnas.1809695115",
language = "English (US)",
volume = "115",
pages = "E9640--E9648",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
publisher = "National Academy of Sciences",
number = "41",
}